Vertex Eyes Triple Glory After Hat Trick of CF Approvals

Vertex Pharmaceuticals Inc.'s domination of the cystic fibrosis market continues apace with the US Food and Drug Administration giving the nod to Symdeko, the company's third disease-modifying treatment to be approved for the rare genetic disorder.

Symdeko combines tezacaftor, which restores CFTR (cystic fibrosis transmembrane conductance regulator) gene function by moving the protein into the correct position on the cell surface, with the company's already-approved Kalydeco (ivacaftor). The approval, which came ahead of a Feb